Selank N-Acetyl is a prescription therapy used for calmness and mood support.

Patients seeking support for calmness and mood support may qualify after evaluation by a licensed provider.

Yes. Selank N-Acetyl is a compounded nasal spray that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure Selank is appropriate for your health history, goals, and current medications.

Selank N-Acetyl is generally well-tolerated at therapeutic doses. Mild nasal irritation, congestion, or transient burning upon administration are the most commonly reported effects with intranasal delivery. Some patients report mild drowsiness or sedation during initial dosing, particularly those sensitive to GABAergic modulation, which typically resolves as the body adjusts. Transient headache or lightheadedness following administration has been noted in a small number of patients. Changes in mood, emotional tone, or sleep quality may occur as serotonin and dopamine pathways adjust during the initial weeks of use. As with any compounded peptide therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

Selank N-Acetyl is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of severe psychiatric conditions including schizophrenia, bipolar disorder, or active psychosis should not use Selank without thorough psychiatric and provider evaluation. Those with active nasal infections, significant nasal polyps, or recent nasal surgery should not use intranasal therapy until cleared by their provider. Patients on benzodiazepines or other GABAergic medications require careful provider review before starting, as additive sedative or neurochemical effects may occur. Selank has not been studied in pediatric populations and is not indicated for patients under 18. Disclose your full medical history, current medications, and any history of psychiatric conditions before starting treatment.

Selank modulates GABA-A receptor activity and influences serotonin, dopamine, and norepinephrine metabolism — patients on benzodiazepines, SSRIs, SNRIs, or other anxiolytic or antidepressant medications should disclose concomitant use with their provider, as neurochemical effects may be additive. Selank stabilizes enkephalins by inhibiting enkephalinase — patients on opioid medications or naltrexone should discuss concurrent use before starting. Those on immunomodulatory agents should exercise caution given Selank's influence on IL-6, IL-1β, and TNF-α inflammatory signaling. Patients on CNS-active medications of any class should always disclose their full medication list to their provider before beginning treatment.

Patients with a history of severe psychiatric conditions including schizophrenia, bipolar disorder, or active psychosis should not use Selank without thorough psychiatric and provider evaluation, as GABAergic and serotonergic modulation may interact unpredictably with underlying disease activity. Those on antidepressants, anxiolytics, or mood-stabilizing medications require careful provider review before starting, as additive neurochemical effects may alter medication requirements. Patients with significant hepatic or renal impairment require individualized dosing review, as these conditions may affect peptide clearance. Those with active nasal conditions including infections, polyps, or recent nasal surgery should not use intranasal therapy until cleared by their provider. Your provider requires a complete medical history before prescribing and will determine whether Selank is appropriate given your individual health profile.